Tracking Troubled NDAs: New FDA Regs Mean Less Clarity For Investors
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
After an 11-year process, FDA is doing away with “approvable” and “not approvable” letters. The new name (“complete response”) gets rid of the negative connotations of “not approvable.” But it is likely to create more confusion – and less transparency – for investors and the public
You may also be interested in...
Running Late: FDA Review Timelines Lengthen For New Product Applications
FDA is missing more new drug review deadlines: at least seven in the first eight months of this year. The experiences of those delayed applications indicate some interesting ways to interpret what it means when a user fee date comes and goes without an FDA decision. One clear observation: the longer a sponsor has to wait after the user fee deadline, the worse the likely result
Running Late: FDA Review Timelines Lengthen For New Product Applications
FDA is missing more new drug review deadlines: at least seven in the first eight months of this year. The experiences of those delayed applications indicate some interesting ways to interpret what it means when a user fee date comes and goes without an FDA decision. One clear observation: the longer a sponsor has to wait after the user fee deadline, the worse the likely result
J&J’s Doribax Is Subject Of FDA’s First "Complete Response" To An NDA
FDA is seeking additional information on Johnson & Johnson's Doribax (doripenem) prior to approving the antibiotic for the treatment of hospital-acquired pneumonia, including ventilator-associated pneumonia, the company announced Aug. 21